<DOC>
	<DOCNO>NCT00905593</DOCNO>
	<brief_summary>Multi-center , open-label , non-randomized trial evaluate long-term safety efficacy nilotinib . Approximately 20 patient enrol trial 3 center Mexico , mean ongoing patient participate [ CAMN107A2109 ] exclude discontinue patient . During study , patient receive nilotinib orally , dose 400 mg b.i.d . Patients normally receive nilotinib outpatient basis . This trial maximum 24 month follow-up time .</brief_summary>
	<brief_title>Nilotinib Adult Patients With Imatinib-resistant Intolerant Chronic Myeloid Leukemia Blast Crisis , Accelerated Phase Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Having participate Novartis study CAMN107A2109 , Written sign date informed consent prior study procedure perform . Impaired cardiac function , Use therapeutic coumarin derivative ( i.e. , warfarin , acenocoumarol , phenprocoumon ) day study drug administration ; Other concurrent severe and/or uncontrolled medical condition , Patients currently receive treatment medication potential prolong QT interval , patient undergo major surgery recover side effect therapy within 15 day , Patients pregnant breast feed adult reproductive potential employ effective method birth control , OR Patients unwilling unable comply protocol . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>chronic myeloid leukemia ,</keyword>
	<keyword>blast crisis ,</keyword>
	<keyword>accelerated phase ,</keyword>
	<keyword>nilotinib ,</keyword>
	<keyword>imatinib ,</keyword>
	<keyword>resistant ,</keyword>
	<keyword>intolerant ,</keyword>
	<keyword>chronic phase</keyword>
</DOC>